CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) shares crossed below its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $0.97 and traded as low as $0.79. CytomX Therapeutics shares last traded at $0.80, with a volume of 884,253 shares trading hands.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reissued a "neutral" rating on shares of CytomX Therapeutics in a research report on Tuesday, January 7th. Four research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $5.77.
Read Our Latest Research Report on CTMX
CytomX Therapeutics Price Performance
The stock has a 50 day moving average price of $0.93 and a two-hundred day moving average price of $1.06. The company has a market capitalization of $61.04 million, a price-to-earnings ratio of 4.59 and a beta of 1.01.
Hedge Funds Weigh In On CytomX Therapeutics
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. FMR LLC lifted its holdings in shares of CytomX Therapeutics by 17.3% during the 3rd quarter. FMR LLC now owns 284,307 shares of the biotechnology company's stock valued at $335,000 after purchasing an additional 41,949 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of CytomX Therapeutics by 4.4% during the 3rd quarter. Geode Capital Management LLC now owns 803,531 shares of the biotechnology company's stock worth $948,000 after acquiring an additional 34,032 shares during the last quarter. US Bancorp DE acquired a new position in shares of CytomX Therapeutics during the 3rd quarter worth approximately $40,000. Assenagon Asset Management S.A. increased its holdings in shares of CytomX Therapeutics by 32.8% during the 3rd quarter. Assenagon Asset Management S.A. now owns 1,644,168 shares of the biotechnology company's stock worth $1,940,000 after acquiring an additional 405,669 shares during the last quarter. Finally, Virtu Financial LLC acquired a new position in shares of CytomX Therapeutics during the 3rd quarter worth approximately $104,000. Institutional investors own 67.77% of the company's stock.
About CytomX Therapeutics
(
Get Free Report)
CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.
Further Reading
Before you consider CytomX Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CytomX Therapeutics wasn't on the list.
While CytomX Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
